vTv Therapeutics, Inc. Class A ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für vTv Therapeutics, Inc. Class A zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um vTv Therapeutics, Inc. Class A zu Deinem Portfolio hinzuzufügen.
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials
HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the European Association for the Study of Diabetes (EASD) 61st Annual Meeting.
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor confe...
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor confe...
Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes Topline data from CATT1 Phase 3 trial on track for second half 2026 HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmace...
• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of ...
Topline results from CATT1 Phase 3 trial expected in second half of 2026 Topline results from CATT1 Phase 3 trial expected in second half of 2026
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.